VIDEO: ‘The future is bright’ for patients treated with RBX2660 for C. difficile

SAN DIEGO — In a Healio video exclusive from Digestive Disease Week 2022, Paul Feuerstadt, MD, FACG, AGAF, discussed studies assessing the investigational biotherapeutic, RBX2660, for the treatment of Clostridioides difficile.“RBX2660 has consistent safety and efficacy regardless of the patient’s medical history as well as their demographics; this again applies to the notion that patients can broadly be treated with this and have a very effective symptomatic relief of their recurrent C. difficile in a sustained fashion,” Feuerstadt, assistant clinical professor of medicineRead More

Related Articles

2019 Telehealth Bill

In 2019, Florida passed the Telehealth Bill which establishes standards of practice for telehealth services, including patient evaluations, record-keeping, and controlled substances prescribing. The bill…